Corcept Therapeutics Incorporated (CORT)
| Market Cap | 3.27B |
| Revenue (ttm) | 356.03M |
| Net Income (ttm) | 109.40M |
| Shares Out | 115.73M |
| EPS (ttm) | 0.89 |
| PE Ratio | 31.62 |
| Forward PE | 38.02 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $28.14 |
| Previous Close | $28.14 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 27.62 |
| Day's Range | 27.48 - 28.36 |
| Day's Volume | 608,130 |
| 52-Week Range | 10.11 - 28.36 |
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
On Friday, Corcept Therapeutics got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Corcept Therapeutics Sees Its Composite Rating Rise To 96 appeared first on Inve...
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat se...
Corcept Therapeutics (CORT) is leading pharma stocks news on Thursday with approval from the U.S. Patent and Trademark Office's PTAB. The post Pharma Stocks: Why Corcept Therapeutics Stock Is ...
MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat se...
Corcept Therapeutics' (LAUR) CEO Eilif Serck-Hanssen on Q3 2020 Results - Earnings Call Transcript
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript
Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year.
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Quick Version Earnings Call Transcript
Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Corcept Therapeutics (NASDAQ:CORT) fell 4.49% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 22.58% over the past year to $0...
MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate up...
A patent decision on its cortisol therapy Korlym is expected to be rendered next month.
Growth-focused investors may be interested in the following stocks since their price-earnings ratios still trade below 20 and their trailing 12-month earnings per share have grown significantl...
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well.
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat...
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.
The Dow Jones Industrial Average closed at 29,100.50 on Wednesday with a gain of 454.84 points or 1.59%.
DENVER--(BUSINESS WIRE)--Shuman, Glenn & Stecker Investigates Corcept Therapeutics, Inc.
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2020 Results - Earnings Call Transcript
MENLO PARK, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...
MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate...
MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...
MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These 3 Biotech Stocks Are Outperforming Their Peers — Here's Why appeared fir...
Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.
MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...
MENLO PARK, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat ...
As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Is (CORT) Outperforming Other Medical Stocks This Year?
MENLO PARK, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat s...
This biotech company has seen huge growth over the past five years.
Corcept Therapeutics sees its Relative Strength Rating move into the 80-plus level. The post Corcept Therapeutics Shows Rising Price Performance With Jump To 85 RS Rating appeared first on Inv...
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2020 Results - Earnings Call Transcript
Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Given the recovering sentiments, investors should reposition their portfolio for more exposure to the growth space to obtain a nice momentum play.
As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.
Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
MENLO PARK, Calif., April 01, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs that tre...
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat...
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
Corcept Therapeutics, Inc. (CORT) CEO Joseph Belanoff on Q4 2019 Results - Earnings Call Transcript
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clin... [Read more...]
| Industry Biotechnology | Founded 1998 |
| CEO Joseph Belanoff | Employees 206 |
| Stock Exchange NASDAQ | Ticker Symbol CORT |
Financial Performance
In 2019, CORT's revenue was $306.49 million, an increase of 21.99% compared to the previous year's $251.25 million. Earnings were $94.18 million, an increase of 24.89%.
Analyst Forecasts
According to 4 analysts, the average rating for CORT stock is "Buy." The 12-month stock price forecast is 25.75, which is a decrease of -8.49% from the latest price.